• Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

    ソース: Nasdaq GlobeNewswire / 03 5 2022 07:00:01   America/New_York

    WAYNE, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO, and Walter Smith, Scientific and Business Development Consultant, of Aclaris will participate in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on Wednesday, May 11, 2022 at 9:00 a.m. ET.

    A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

    About Aclaris Therapeutics, Inc.

    Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

    Aclaris Contact

    investors@aclaristx.com



    Primary Logo

シェアする